{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T01:35:51Z","timestamp":1769045751042,"version":"3.49.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.pupt.2013.03.020","type":"journal-article","created":{"date-parts":[[2013,4,9]],"date-time":"2013-04-09T03:03:11Z","timestamp":1365476591000},"page":"630-634","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["The effect of indacaterol during an acute exacerbation of COPD"],"prefix":"10.1016","volume":"26","author":[{"given":"Andrea","family":"Segreti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrica","family":"Fiori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigino","family":"Calzetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Sabatini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Segreti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Rogliani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Cazzola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pupt.2013.03.020_bib1","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.mcna.2012.02.008","article-title":"COPD exacerbations: causes, prevention, and treatment","volume":"96","author":"Mackay","year":"2012","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.pupt.2013.03.020_bib2","unstructured":"Global initiative for chronic obstructive lung disease (GOLD) global strategy for the diagnosis, management and prevention of COPD. Available from: http:\/\/www.goldcopd.org; [accessed 11.11.12]."},{"key":"10.1016\/j.pupt.2013.03.020_bib3","series-title":"Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care","author":"National Clinical Guideline Centre, London National Clinical Guideline Centre","year":"2010"},{"key":"10.1016\/j.pupt.2013.03.020_bib4","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/BF02575304","article-title":"Dose\u2013response effects and time course of effects of inhaled fenoterol on respiratory mechanics and arterial oxygen tension in mechanically ventilated patients with chronic airflow obstruction","volume":"16","author":"Bernasconi","year":"1990","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.pupt.2013.03.020_bib5","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S0196-0644(97)70219-1","article-title":"Effect of different albuterol dosing regimens in the treatment of acute exacerbation of chronic obstructive pulmonary disease","volume":"29","author":"Emerman","year":"1997","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.pupt.2013.03.020_bib6","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1378\/chest.98.4.835","article-title":"A\u00a0comparison of the effects of ipratropium bromide and metaproterenol sulfate in acute exacerbations of COPD","volume":"98","author":"Karpel","year":"1990","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2013.03.020_bib7","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S1094-5539(03)00025-7","article-title":"Long-acting \u03b22 agonists as potential option in the treatment of acute exacerbations of COPD","volume":"16","author":"Cazzola","year":"2003","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.pupt.2013.03.020_bib8","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1053\/rmed.2001.1172","article-title":"Formoterol turbuhaler for as-needed therapy in patients with mild acute exacerbations of COPD","volume":"95","author":"Cazzola","year":"2001","journal-title":"Respir Med"},{"key":"10.1016\/j.pupt.2013.03.020_bib9","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1358\/dot.2010.46.3.1450070","article-title":"Indacaterol for chronic obstructive pulmonary disease (COPD)","volume":"46","author":"Cazzola","year":"2010","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.pupt.2013.03.020_bib10","first-page":"311","article-title":"Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasone","volume":"5","author":"Balint","year":"2010","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.pupt.2013.03.020_bib11","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1164\/rccm.200703-456SO","article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary","volume":"176","author":"Rabe","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pupt.2013.03.020_bib12","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1183\/09031936.00015807","article-title":"Troponin T elevation and long-term mortality after chronic obstructive pulmonary disease exacerbation","volume":"31","author":"Brekke","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2013.03.020_bib13","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.2165\/00003495-200565120-00001","article-title":"Inhaled \u03b22-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease","volume":"65","author":"Cazzola","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.pupt.2013.03.020_bib14","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1378\/chest.114.2.411","article-title":"Cardiac effects of formoterol and salmeterol in patients suffering from\u00a0COPD with preexisting cardiac arrhythmias and hypoxemia","volume":"114","author":"Cazzola","year":"1998","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2013.03.020_bib15","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1136\/thx.2010.153122","article-title":"Elevated high-sensitivity cardiac troponin T is associated with increased mortality after acute exacerbation of chronic obstructive pulmonary disease","volume":"66","author":"H\u00f8iseth","year":"2011","journal-title":"Thorax"},{"key":"10.1016\/j.pupt.2013.03.020_bib16","first-page":"341","article-title":"Prognostic value of cardiac troponin I in patients with COPD acute exacerbation","volume":"67","author":"Martins","year":"2009","journal-title":"Neth J Med"},{"key":"10.1016\/j.pupt.2013.03.020_bib17","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.rmed.2005.04.024","article-title":"Effect of formoterol\/budesonide combination on arterial blood gases in patients with acute exacerbation of COPD","volume":"100","author":"Cazzola","year":"2006","journal-title":"Respir Med"},{"key":"10.1016\/j.pupt.2013.03.020_bib18","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1378\/chest.125.6.2309","article-title":"Cardiovascular effects of \u03b2-agonists in patients with asthma and COPD","volume":"125","author":"Salpeter","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2013.03.020_bib19","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.rmed.2010.11.027","article-title":"Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD","volume":"105","author":"Worth","year":"2011","journal-title":"Respir Med"},{"key":"10.1016\/j.pupt.2013.03.020_bib20","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2147\/COPD.S23816","article-title":"Safety of indacaterol in the treatment of patients with COPD","volume":"6","author":"Donohue","year":"2011","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.pupt.2013.03.020_bib21","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.ejheart.2006.01.010","article-title":"Heart failure and chronic obstructive pulmonary disease: an ignored combination?","volume":"8","author":"Rutten","year":"2006","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.pupt.2013.03.020_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pupt.2009.10.001","article-title":"Pharmacological modulation of \u03b2-adrenoceptor function in patients with coexisting chronic obstructive pulmonary disease and chronic heart failure","volume":"23","author":"Matera","year":"2010","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.pupt.2013.03.020_bib23","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1067\/mhj.2001.118117","article-title":"Left ventricular diastolic dysfunction in patients with bronchial asthma with long-term oral \u03b22-adrenoceptor agonists","volume":"142","author":"Hirono","year":"2001","journal-title":"Am Heart J"},{"key":"10.1016\/j.pupt.2013.03.020_bib24","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1378\/chest.123.6.1964","article-title":"Risk of mortality and heart failure exacerbations associated with inhaled \u03b2-adrenoceptor agonists among patients with known left ventricular systolic dysfunction","volume":"123","author":"Au","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2013.03.020_bib25","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jacc.2006.08.046","article-title":"Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure","volume":"49","author":"Le Jemtel","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.pupt.2013.03.020_bib26","first-page":"w1329","article-title":"Use of brain natriuretic peptide to detect previously unknown left ventricular dysfunction in patients with acute exacerbation of chronic obstructive pulmonary disease","volume":"141","author":"Gariani","year":"2011","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.pupt.2013.03.020_bib27","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1378\/chest.07-1959","article-title":"Use of B-type natriuretic peptide in the risk stratification of acute exacerbations of COPD","volume":"133","author":"Stolz","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2013.03.020_bib28","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.pupt.2006.02.002","article-title":"Doppler echocardiographic assessment of the effects of inhaled long-acting \u03b22-agonists on pulmonary artery pressure in COPD patients","volume":"20","author":"Cazzola","year":"2007","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.pupt.2013.03.020_bib29","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1161\/01.CIR.0000106903.98196.B6","article-title":"Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure","volume":"108","author":"Tang","year":"2003","journal-title":"Circulation"}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553913001065?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553913001065?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T03:03:08Z","timestamp":1539745388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553913001065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S1094553913001065"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2013.03.020","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of indacaterol during an acute exacerbation of COPD","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2013.03.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}